Lexaria Bioscience Analyst Price Targets

Lexaria Bioscience Corp

LEXXNASDAQ

Trade with Public

$2.86

-0.13-4.35%

Dern. MÀJ: Oct 19, 8:28 AM

$2.80

-0.19-6.35%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Rapport sur les stocks

Lexaria Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lexaria Bioscience (LEXX).

Price Target Range — 6 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingBuy# Analysts2Avg. Consensus PT$101Upside to Avg. PT+3516.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Dec 26, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$4→$2
Jul 29, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$5→$4
Jul 1, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$7→$5
Jan 24, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$10→$7
Dec 2, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$10
Nov 25, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$10
Jul 18, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$10
Jul 10, 2024	HC Wainwright & Co.	Yi Chen	Initiate	Buy	$10
Mar 5, 2024	Maxim Group	Michael Okunewitch	PT Raise	Buy	$3→$12

More with Benzinga EdgeGet Access

Analyst Ratings News

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $4 to $1.5.

Benzinga Newsdesk

PRO
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07312025_LEXX_Vandermosten.pdf

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $5 to $4.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $7 to $5.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7

HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $10 to $7.

Benzinga Newsdesk

Lexaria Bioscience Corp

Lexaria Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

PRO
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Lexaria Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

PRO
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7

People Also Watch

People Also Watch

Lexaria Bioscience Corp

Lexaria Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

PROWatching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Lexaria Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

PROWatching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

PROHC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

PRO
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5

PRO
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

PRO
HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $7